Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
A long-term study evaluating the efficacy and safety of linagliptin in patients with type 2 diabetes was selected by EASD as an oral presentation, taking place on
The presentations are as follows:
Linagliptin Data | ||||
Title | Format | Authors | Date/Time | |
Preclinical DPP-4 Inhibition - A New Approach for the Treatment of Uraemic Cardiomyopathy | Poster 824-P | L Chaykovska, K von Websky, S Heiden, J Rahnenfuhrer, T Klein, B Hocher | Date: Tues, Sept. 13 Time: 12:30−1:30 p.m. | |
Phase III (52-week) Long-term Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes and Severe Renal Impairment | Poster 821-P | J Newman, J McGill, S Patel, C Friedrich, C Sauce, H-J Woerle | Date: Tues, Sept. 13 Time: 12:30−1:30 p.m. | |
Phase III (pooled analysis) Linagliptin Improves Glycemic Control Independently of Diabetes Duration and Insulin Resistance in Patients with Type 2 Diabetes | Poster 832-P | S Patel, S-A Weber, A Emser, | Date: Tues, Sept. 13 Time: 1:30−2:30 p.m. | |
Phase II (12-week) Efficacy and Safety of 5 mg Daily Dosing Regimens with Linagliptin in Patients with Type 2 Diabetes Inadequately Controlled on Metformin | Poster 831-P | E Rafeiro, S Ross, T Meinicke, R Toorawa, H-J Woerle | Date: Tues, Sept. 13 Time: 1:30−2:30 p.m. | |
Preclinical Effect of Linagliptin on Infarction Size and Cardiac Function in Rats After Myocardial Ischaemia Reperfusion | Poster 811-P | T Pfab, Y Sharkovska, M Alter, K von Websky, M Mark, T Klein, B Hocher | Date: Thurs, Sept. 15 Time: 1:30−2:30 p.m. | |
Phase III (104 week) Long-term Efficacy and Safety of the DPP-4 Inhibitor Linagliptin: Data from a Large Two-year Study in Patients with Type 2 Diabetes Mellitus | Oral Presentation 242-OP | A Schlosser, D Owens, M-R Taskinen, S Del Prato, R Gomis, S Patel, A Pivovarova, H-J Woerle | Date: Fri, Sept. 16 Time: 11:45 a.m.−12:00 p.m. | |
Empagliflozin Data | ||||
Title | Format | Authors | Date/Time | |
Phase II (12 week) ENCORE: Efficacy and Safety of BI-10773, a new Sodium Glucose Co-transporter-2 (SGLT-2) Inhibitor, in Type 2 Diabetes Patients Inadequately Controlled on Metformin | Oral Presentation 147-OP | L Seman, J Rosenstock, A Jelaska, S Pinnetti, S Hantel, H-J Woerle | Date: Thurs, Sept. 15 Time: 11:15−11:30 a.m. | |
*All times in Western European Summer Time (WEST) | ||||
Indication and Important Limitations of Use
TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
TRADJENTA has not been studied in combination with insulin.
Important Safety Information
CONTRAINDICATIONS
TRADJENTA is contraindicated in patients with a history of hypersensitivity reaction to linagliptin, such as urticaria, angioedema or bronchial hyperreactivity.
WARNINGS AND PRECAUTIONS
Use with Medications Known to Cause Hypoglycemia
Insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Therefore, a lower dose of the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with TRADJENTA.
Macrovascular Outcomes
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with TRADJENTA or any other antidiabetic drug.
ADVERSE REACTIONS
Adverse reactions reported in >/=5% of patients treated with TRADJENTA and more commonly than in patients treated with placebo included nasopharyngitis.
Hypoglycemia was more commonly reported in patients treated with the combination of TRADJENTA and sulfonylurea compared with those treated with the combination of placebo and sulfonylurea. Pancreatitis was reported more often in patients randomized to linagliptin (1 per 538 person-years versus zero in 433 person-years for comparator).
DRUG INTERACTIONS
The efficacy of TRADJENTA may be reduced when administered in combination with a strong P-glycoprotein or CYP3A4 inducer (e.g., rifampin). Therefore, use of alternative treatments is strongly recommended.
USE IN SPECIFIC POPULATIONS
There are no adequate and well-controlled studies in pregnant women. Therefore, TRADJENTA should be used during pregnancy only if clearly needed. It is not known whether linagliptin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRADJENTA is administered to a nursing woman. Safety and effectiveness of TRADJENTA in patients below the age of 18 have not been established.
To learn more about TRADJENTA and for full prescribing information visit: www.TRADJENTA.com or call
Please report any unexpected effects or product problems to the Boehringer Ingelheim Drug Information Unit by calling 1-800-542-6257.
You are encouraged to report negative side effects of prescription drugs to the
About Diabetes
Approximately 25.8 million Americans(1) and an estimated 220 million people(2) worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.(1) Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.(3)
Boehringer Ingelheim and
In
About
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim,
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2010, Boehringer Ingelheim posted net sales of approximately
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
About
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
About Lilly Diabetes
For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy — practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com.
P-LLY
TJ110803 PR
(1)
(2)
(3)
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
(Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO )
SOURCE
News Provided by Acquire Media